Navigation Links
Martek Signs Sole-Source Supply Agreement with Fonterra
Date:12/10/2009

Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited for the use of Martek’s products in Fonterra’s infant formulas and milk-based Anmum™ Materna products for pregnant and nursing mothers.

Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited for the use of Martek’s products in Fonterra’s infant formulas and milk-based Anmum™ Materna products for pregnant and nursing mothers.

Fonterra’s infant formulas, featuring life’sDHA™ and life’sARA™, will be available in Malaysia, Indonesia and China.

Fonterra’s Anmum™ Materna products for pregnant and nursing mothers, featuring life’sDHA, will be available in Indonesia, Taiwan, Hong Kong, the Philippines, Malaysia, Vietnam, Singapore, Thailand and China.

“Martek is a leading global supplier of DHA and ARA. Infant formulas containing Martek’s
life’sDHA and life’sARA can be found in more than 75 countries worldwide, and we continue to expand our international presence in the infant formula and perinatal markets,” said Ethan Leonard, vice president of pediatric nutrition for Martek. “Our sole-source supply arrangement with Fonterra further demonstrates that companies worldwide understand the importance of adding Martek’s DHA and ARA to infant formula and perinatal products for infant health and development.”

Naturally present in human breast milk, DHA (docosahexaenoic acid), and ARA (arachidonic acid) are fatty acids important to infant development and growth. Clinical studies have demonstrated numerous benefits for infants receiving DHA and ARA supplemented formula, including improved mental and visual development.
DHA also is important throughout pregnancy, particularly in the third trimester when significant brain growth occurs. Maternal DHA supplementation during pregnancy and nursing significantly enhances the level of DHA available to the fetus and infant. Studies have shown that maternal DHA supplementation may improve infant developmental outcomes, such as eye-hand coordination, motor skills and attention span.

Martek's blend of DHA and ARA, life’sDHA & life’sARA, is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Martek’s life’sDHA can also be found around the world in a range of supplements and other products intended for use during pregnancy and breastfeeding.

Fonterra is the world’s leading exporter of dairy products and responsible for more than a third of international dairy trade. Its dairy farmers have long been known for producing quality milk and today Fonterra is a world leader in dairy commodities and premium ingredients, and has regional consumer brands businesses in Australasia, Asia, the Middle East and Latin America. Fonterra’s global supply chain stretches from farms all over New Zealand to customers and consumers in more than 140 countries. Fonterra currently manufactures the Anmum™ brand of premium milk formulas for pregnant and nursing mothers, as well as for infants and toddlers.

Martek Biosciences Corporation is a leader in the innovation and development of DHA and ARA and has developed patented technology for the production and use of these ingredients. DHA omega-3 products promote health and wellness through every stage of life and ARA omega-6 products support growth and development in infants and children. The company produces life'sDHA™, a sustainable vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, perinatal products, and supplements, and life’sARA™, a sustainable vegetarian source of ARA omega-6, for use in infant formula and growing up milks. For more information on Martek Biosciences, visit http://www.martek.com/. For more information on products containing lifesDHA and life’sARA, visit www.lifesdha.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

# # #

Read the full story at http://www.prweb.com/releases/dairy_fonterra/martek_biosciences/prweb3321614.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
2. Martek Announces Addition to Its Board of Directors
3. Martek to Present at Two Upcoming Investor Conferences
4. Martek Announces Settlement of Patent Dispute with Capsugel France
5. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
6. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
7. Martek to Announce Third Quarter 2009 Results
8. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.
9. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
10. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
11. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Martek Signs Sole-Source Supply Agreement with Fonterra
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):